Bharat Immunologicals & Biologicals Corporation Limited announced unaudited earnings results for the fourth quarter and full year ended March 31, 2018. For the quarter, the company reported income from operations of INR 216.806 million against INR 613.418 million for the same period a year ago. Total revenue was INR 223.048 million against INR 615.576 million for the same period a year ago. Loss before finance cost and exceptional items was INR 40.980 million against profit before finance cost and exceptional items of INR 59.879 million for the same period a year ago. Loss from continuing operations was INR 13.060 million against profit from continuing operations of INR 40.818 million for the same period a year ago. Basic and diluted loss per share was INR 0.30 against basic and diluted earnings per share of INR 0.95 for the same period a year ago. For the year, the company reported income from operations of INR 347.988 million against INR 1,241.851 million for the same period a year ago. Total revenue was INR 363.143 million against INR 1,253.619 million for the same period a year ago. Loss before finance cost and exceptional items was INR 78.999 million against profit before finance cost and exceptional items of INR 94.544 million for the same period a year ago. Loss from continuing operations was INR 51.726 million against profit from continuing operations of INR 67.451 million for the same period a year ago. Basic and diluted loss per share was INR 1.20 against basic and diluted earnings per share of INR 1.56 for the same period a year ago.